Compugen to Participate in Upcoming Investor Conferences

Compugen Ltd. (NASDAQ: CGEN, TASE: CGEN), a clinical-stage company at the forefront of cancer immunotherapy and driven by AI/ML technologies, recently announced its participation in several upcoming investor conferences. The company is set to engage in two key events: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, and the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026. Both appearances will feature fireside chat sessions, providing an opportunity for management to discuss the company's innovative approaches and pipeline developments.

Compugen is renowned for its Unigen™ computational discovery platform, which enables the identification of unique drug targets and biological pathways for cancer treatments. The company's prominent programs include COM902, an Fc-reduced high-affinity anti-TIGIT antibody undergoing Phase 1 trials, and rilvegostomig, a bispecific antibody directed against both PD-1 and TIGIT that is currently in Phase 3 development via a partnership with AstraZeneca. Rilvegostomig incorporates the TIGIT component from COM902, reflecting the interconnectedness of Compugen’s advancements. Additionally, the company is progressing with COM701, a first-in-class anti-PVRIG antibody in Phase 1 trials, and GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead.

Compugen's strategic focus on early-stage immuno-oncology programs and innovative therapies positions it strongly within the competitive landscape of cancer immunotherapy. For interested investors and stakeholders, live webcasts of the fireside chats will be accessible through the Investor Relations section of Compugen's website, alongside replays post-event. This initiative represents a concerted effort by Compugen to bolster its visibility and communicate its vision and progress to the investment community.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company leveraging AI and machine learning in drug discovery, is gearing up to participate in two notable investor conferences this February and March. These events represent strategic opportunities for both the company and its investors, particularly as the market looks for innovation in the oncology space.

Investors should view Compugen’s participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26 and the Leerink Partners 2026 Global Healthcare Conference on March 9 as significant indicators of ongoing engagement with the investment community. With management set to present through fireside chats and one-on-one meetings, this will provide crucial insights into the company’s research and development trajectory, especially regarding its advanced clinical programs like COM902 and the bispecific antibody rilvegostomig.

The company has a strong pipeline that includes the potential best-in-class anti-TIGIT antibody critical for stimulating an immune response against tumors, as well as the unique Unigen™ platform, which sets Compugen apart by identifying novel drug targets. Given the increasing focus on immunotherapy within oncology, these upcoming presentations may attract heightened interest from institutional investors looking for innovative biotech firms.

While Compugen's stock may experience volatility leading up to and following the conferences, any positive news, updates, or strategic partnerships announced during these events could significantly catalyze share price appreciation. For those considering entry or expansion in their positions, monitoring these conferences offers an advantageous moment to evaluate market sentiment and trajectory for Compugen. Following the webcasts, investors should assess the information shared as part of their ongoing due diligence process, particularly regarding advancements in clinical trial outcomes, to inform future investment decisions.